Log in to save to my catalogue

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune s...

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune s...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9436a920f67a4275b778a98aec3608cb

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

About this item

Full title

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Publisher

England: BioMed Central Ltd

Journal title

Genome medicine, 2022-01, Vol.14 (1), p.1-15, Article 1

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

A limited number of studies have characterized genomic properties of hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy.
Herein, we performed comprehensive molecular characterization of immediate (D-42 to D-1) pre-treatment tumor biopsy specimens from 60 patients with sorafenib-failed HCC in a single-arm prospective p...

Alternative Titles

Full title

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_9436a920f67a4275b778a98aec3608cb

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9436a920f67a4275b778a98aec3608cb

Other Identifiers

ISSN

1756-994X

E-ISSN

1756-994X

DOI

10.1186/s13073-021-00995-8

How to access this item